 IRVINE, CA ACCESSWIRE November 15, 2019 Hancock Jaffe Laboratories, Inc. HJLINASDAQ:HJLIW, a developer of medical devices that restore cardiac and vascular health, announced today that it has enrolled and successfully implanted the 10th patient to complete the initial implantation phase of the first-in-man VenoValve study being conducted in Colombia. Hancock Jaffes first-in-man study is the precursor to seeking permission from the U.S. Food and Drug Administration FDA to conduct the VenoValve U.S. pivotal trial. In consultation with the FDA, HJLI agreed to conduct a first-in-man study of between five and ten patients that suffer from chronic venous insufficiency CVI. 